Asa Cox Founder genericlicensing.com Strategic Portfolio Planning  for Generic Drugs May 12, 2010
- 13 years in generics Manufacturing, Development, Licensing, Consulting - International projects - Online networker - Web...
<ul><li>Overview of typical generic portfolio’s - Specifics of portfolio planning for generics </li></ul><ul><li>- Why str...
<ul><li>Does typical exist?! </li></ul><ul><ul><li>Country variables: </li></ul></ul><ul><ul><li>Demographic  </li></ul></...
<ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g  United Kingdom </li></...
<ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g  United Kingdom </li></...
<ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g  United Kingdom </li></...
<ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g  United Kingdom </li></...
<ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g  United Kingdom </li></...
If you were creating a portfolio from scratch... where would you start?! Specifics of portfolio planning for generics
<ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></u...
<ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></u...
<ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></u...
<ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></u...
<ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></u...
<ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></u...
Specifics of portfolio planning for generics <ul><li>Using IMS – Top Generics </li></ul><ul><li>Top 200 </li></ul><ul><li>...
Specifics of portfolio planning for generics 1. Fentanyl Launched: January 2005,  2008 sales: $800 million Branded equival...
Specifics of portfolio planning for generics 5. Risperidone Launched: September 2008, 2008 sales: $610 million,  Branded e...
Specifics of portfolio planning for generics <ul><li>Using IMS – Top Generics </li></ul><ul><li>Why difference in generic ...
EXAMPLE : OMEPRAZOLE – US vs UK US - $300m value erosion (25%) UK -  Specifics of portfolio planning for generics
OMEPRAZOLE – UK (£25 to £1) Specifics of portfolio planning for generics
Specifics of portfolio planning for generics Targeting patent expiry of a blockbuster?!
Specifics of portfolio planning for generics CLOPIDOGREL/PLAVIX
Specifics of portfolio planning for generics CLOPIDOGREL/PLAVIX
Specifics of portfolio planning for generics <ul><li>If you were creating a portfolio from scratch... where would you star...
Why  strategic  planning is important
Why  strategic  planning is important 2009 global generic products generated $83bn (€59.8bn) in audited sales (IMS)
Why  strategic  planning is important 2009 global generic products generated $83bn (€59.8bn) in audited sales (IMS)  In th...
Why  strategic  planning is important 2009 global generic products generated $83bn (€59.8bn) in audited sales, according t...
Why  strategic  planning is important Government debt as % of GDP (2009)
Why  strategic  planning is important
Why  strategic  planning is important
Why  strategic  planning is important IMS estimates that sales from the top 10 US generic players grew at an average of 13...
Why  strategic  planning is important The big can get bigger still!
Why  strategic  planning is important The big can get bigger still! &quot;Only those who are agile and  strong  will survi...
Why  strategic  planning is important The big can get bigger still! Teva estimates its 2009 global sales at $13.9bn, of wh...
Why  strategic  planning is important Biosimilars/follow on biologics Approximately one-third of all newly approved drugs ...
Why  strategic  planning is important
Why  strategic  planning is important Biosimilars/follow on biologics
Why  strategic  planning is important The patent cliff: 2010-15  Of total pharmaceutical sales in 2008 of $643.6bn, a stag...
Why  strategic  planning is important The patent cliff: 2010-15  The world's top drugmakers face the loss of $140 billion ...
Why  strategic  planning is important The patent cliff: 2010-15  Inhalation market Approximately  50% of the current $32 b...
Why  strategic  planning is important The patent cliff: 2010-15  &quot;There is still room to grow in generics,&quot; says...
Overview of typical generic portfolio’s <ul><li>The patent cliff: 2010-15 </li></ul><ul><li>Whats the big pharma plan? </l...
The patent cliff: 2010-15.  Whats the big pharma plan? Astra Zeneca  announced today that it has agreed to market 18 of To...
The patent cliff: 2010-15.  Whats the big pharma plan? Sanofi-Aventis  bought  Zentiva  NV of the Czech Republic,  Helveph...
The patent cliff: 2010-15.  Whats the big pharma plan? “ Generics are an important part of the health care system.  ????? ...
The patent cliff: 2010-15.  Whats the big pharma plan? “ Generics are an important part of the health care system.  Pfizer...
The patent cliff: 2010-15.  Whats the big pharma plan? NEW YORK, March 18 (Reuters) -  Pfizer  Inc ( PFE.N ) may still be ...
The patent cliff: 2010-15.  Whats the big pharma plan? Pfizer’s global annual sales of established products are approximat...
The patent cliff: 2010-15.  Whats the big pharma plan? Last year,  GlaxoSmithKline  entered into joint ventures with the  ...
Why strategic planning is important <ul><li>SUMMARY : What is the future going to look like?! </li></ul><ul><li>5 year hig...
Introduction to sourcing from 3rd parties <ul><li>Creating the portfolio – why look outside </li></ul><ul><li>Manufacturin...
Introduction to sourcing from 3rd parties <ul><li>Creating the portfolio –  where to look </li></ul><ul><li>Emerging marke...
Introduction to sourcing from 3rd parties <ul><li>Creating the portfolio –  considerations </li></ul><ul><li>Partner Selec...
Summary <ul><li>What type of portfolio do you want? - Selecting generic products isn’t easy </li></ul><ul><li>- Why strate...
Upcoming SlideShare
Loading in …5
×

Strategic generic portfolio selection may 12th 2010

4,592 views

Published on

How do you decide what generic product to develop?

Published in: Business
1 Comment
2 Likes
Statistics
Notes
No Downloads
Views
Total views
4,592
On SlideShare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
299
Comments
1
Likes
2
Embeds 0
No embeds

No notes for slide

Strategic generic portfolio selection may 12th 2010

  1. 1. Asa Cox Founder genericlicensing.com Strategic Portfolio Planning for Generic Drugs May 12, 2010
  2. 2. - 13 years in generics Manufacturing, Development, Licensing, Consulting - International projects - Online networker - Web business 2.0 believer About me
  3. 3. <ul><li>Overview of typical generic portfolio’s - Specifics of portfolio planning for generics </li></ul><ul><li>- Why strategic planning is important for generic companies </li></ul><ul><li>Introduction to sourcing generic products from 3rd parties </li></ul><ul><li>Aim: To understand why strategy and planning for generic portfolio’s is required! </li></ul>Topics
  4. 4. <ul><li>Does typical exist?! </li></ul><ul><ul><li>Country variables: </li></ul></ul><ul><ul><li>Demographic </li></ul></ul><ul><ul><li>Population </li></ul></ul><ul><ul><li>Market development </li></ul></ul><ul><ul><li>Local players </li></ul></ul><ul><ul><li>Drug provision policy </li></ul></ul><ul><ul><li>Generic incentives </li></ul></ul><ul><ul><li>Economy </li></ul></ul>Overview of typical generic portfolio’s
  5. 5. <ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g United Kingdom </li></ul>Overview of typical generic portfolio’s
  6. 6. <ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g United Kingdom </li></ul><ul><li>Full : Teva, Actavis, Sandoz, Mylan </li></ul>Overview of typical generic portfolio’s
  7. 7. <ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g United Kingdom </li></ul><ul><li>Full : Teva, Actavis, Sandoz, Mylan </li></ul><ul><li>Profit: Arrow, Ratiopharm, Winthrop, Stada </li></ul>Overview of typical generic portfolio’s
  8. 8. <ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g United Kingdom </li></ul><ul><li>Full : Teva, Actavis, Sandoz, Mylan, </li></ul><ul><li>Profit: Arrow, Ratiopharm, Winthrop, Stada </li></ul><ul><li>Focused: Rosemont, Hospira, Perrigo </li></ul>Overview of typical generic portfolio’s
  9. 9. <ul><li>Does typical exist?! </li></ul><ul><li>Typical category portfolio’s? </li></ul><ul><li>e.g United Kingdom </li></ul><ul><li>Full : Teva, Actavis, Sandoz, Mylan, </li></ul><ul><li>Profit: Arrow, Ratiopharm, Winthrop, Stada </li></ul><ul><li>Focused: Rosemont, Hospira, Perrigo </li></ul><ul><li>Manufacturing: Cipla, Ranbaxy, Wockhardt, Aurobindo... </li></ul>Overview of typical generic portfolio’s
  10. 10. If you were creating a portfolio from scratch... where would you start?! Specifics of portfolio planning for generics
  11. 11. <ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></ul><ul><ul><li>Business plan/strategy </li></ul></ul><ul><ul><li>Cost of entry </li></ul></ul><ul><ul><li>Available technology </li></ul></ul><ul><ul><li>Risk of competition </li></ul></ul><ul><ul><li>Supply chain </li></ul></ul>Specifics of portfolio planning for generics
  12. 12. <ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></ul><ul><li>IMS top down </li></ul><ul><ul><li>Value or volume </li></ul></ul><ul><ul><li>Level of competition </li></ul></ul><ul><ul><li>- Same data as everyone! </li></ul></ul><ul><ul><li>Manufacturing capability </li></ul></ul>Specifics of portfolio planning for generics
  13. 13. <ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></ul><ul><li>IMS top down </li></ul><ul><li>Patent expiries </li></ul><ul><ul><li>Originator tactics </li></ul></ul><ul><ul><li>Timing </li></ul></ul><ul><ul><ul><li>- First in reaps rewards </li></ul></ul></ul><ul><ul><li>At risk vs late to the party </li></ul></ul><ul><ul><li>- Legal costs & expertise </li></ul></ul><ul><ul><li>COGS vs ASP </li></ul></ul><ul><ul><ul><li>- Stock vs cash </li></ul></ul></ul><ul><ul><ul><li>- Loss vs market share </li></ul></ul></ul>Specifics of portfolio planning for generics
  14. 14. <ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></ul><ul><li>IMS top down </li></ul><ul><li>Patent expiries </li></ul><ul><li>Manufacturing capability </li></ul><ul><ul><li>Dose forms </li></ul></ul><ul><ul><li>Biologics </li></ul></ul><ul><ul><li>Capacity </li></ul></ul><ul><ul><li>Dedicated units </li></ul></ul><ul><ul><li>Supply chain </li></ul></ul><ul><ul><li>Cost </li></ul></ul>Specifics of portfolio planning for generics
  15. 15. <ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></ul><ul><li>IMS top down </li></ul><ul><li>Patent expiries </li></ul><ul><li>Manufacturing capability </li></ul><ul><li>Marketing & Distribution </li></ul><ul><ul><li>Rx or OTC </li></ul></ul><ul><ul><li>- Branded or Private Label </li></ul></ul><ul><ul><li>- Standard or Generic+ </li></ul></ul><ul><ul><li>Hospital or retail </li></ul></ul><ul><ul><ul><ul><li>- Wholesale, Multiples, Independent, Online </li></ul></ul></ul></ul><ul><ul><li>Positioning </li></ul></ul><ul><ul><li>- Service, Price, Depth, Speciality, Product Type </li></ul></ul>Specifics of portfolio planning for generics
  16. 16. <ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>Cash vs Profit </li></ul><ul><li>IMS top down </li></ul><ul><li>Patent expiries </li></ul><ul><li>Manufacturing capability </li></ul><ul><li>Marketing & Distribution </li></ul><ul><li>Copy Competition </li></ul><ul><ul><li>Which one?! </li></ul></ul><ul><ul><li>Response </li></ul></ul><ul><ul><li>Attainability </li></ul></ul>Specifics of portfolio planning for generics
  17. 17. Specifics of portfolio planning for generics <ul><li>Using IMS – Top Generics </li></ul><ul><li>Top 200 </li></ul><ul><li>All over $400m </li></ul><ul><li>Very long tail </li></ul>
  18. 18. Specifics of portfolio planning for generics 1. Fentanyl Launched: January 2005, 2008 sales: $800 million Branded equivalent: Duragesic, by Janssen 2008 sales of $250 million (from $1.1 billion) 2. Amlodipine besylate and benazepril hydrochloride* Launched: July 2007, 2008 sales: $779 million Branded equivalent: Norvasc, by Pfizer 2008 sales <$150m ($1.5 billion) 3. Metoprolol succinate Launched: May 2008, 2008 sales: $675 million Branded equivalent: Toprol, by AstraZeneca 2008 sales <$150m ($807 million) 4. Lamotrigine Launched: February 2005, 2008 sales: $671 million Branded equivalent: Lamictal, by GlaxoSmithKline 2008 sales $1.6 billion (peak) Using IMS – Top Generics
  19. 19. Specifics of portfolio planning for generics 5. Risperidone Launched: September 2008, 2008 sales: $610 million, Branded equivalent: Risperdal, by Janssen, 2008 sales $1.5b ($2.1 billion) 6. Omeprazole* Launched: July 2008, 2008 sales: $609.8 million Branded equivalent: Prilosec, by AstraZeneca, 2008 sales $185m ($1.1 billion) 7. Azithromycin Launched: November 2005, 2008 sales: $599 million, Branded equivalent: Zithromax, by Pfizer, 2008 sales <$150m ($1.7 billion) 8. Bupropion Launched: December 2006, 2008 sales: $521 million Branded equivalent: Wellbutrin, by Biovail, 2008 sales $579 million ($1.7 billion) Using IMS – Top Generics
  20. 20. Specifics of portfolio planning for generics <ul><li>Using IMS – Top Generics </li></ul><ul><li>Why difference in generic success? </li></ul><ul><ul><li>Brand tactics </li></ul></ul><ul><ul><ul><li>Price match </li></ul></ul></ul><ul><ul><ul><li>Alternative formulations </li></ul></ul></ul><ul><ul><ul><li>Effective anti-generic messages </li></ul></ul></ul><ul><ul><li>Doctor perspective </li></ul></ul><ul><ul><ul><li>Long term use </li></ul></ul></ul><ul><ul><ul><li>Activity limits </li></ul></ul></ul>
  21. 21. EXAMPLE : OMEPRAZOLE – US vs UK US - $300m value erosion (25%) UK - Specifics of portfolio planning for generics
  22. 22. OMEPRAZOLE – UK (£25 to £1) Specifics of portfolio planning for generics
  23. 23. Specifics of portfolio planning for generics Targeting patent expiry of a blockbuster?!
  24. 24. Specifics of portfolio planning for generics CLOPIDOGREL/PLAVIX
  25. 25. Specifics of portfolio planning for generics CLOPIDOGREL/PLAVIX
  26. 26. Specifics of portfolio planning for generics <ul><li>If you were creating a portfolio from scratch... where would you start?! </li></ul><ul><li>SUMMARY: </li></ul><ul><li>Commercial strategy </li></ul><ul><ul><li>Profit or volume </li></ul></ul><ul><li>Market strategy </li></ul><ul><ul><li>Distribution channels </li></ul></ul><ul><ul><li>Classification type </li></ul></ul><ul><li>Manufacturing capability </li></ul><ul><ul><li>Product type </li></ul></ul><ul><li>Legal & Regulatory expertise </li></ul><ul><ul><li>Patent expiry vs long tail </li></ul></ul>
  27. 27. Why strategic planning is important
  28. 28. Why strategic planning is important 2009 global generic products generated $83bn (€59.8bn) in audited sales (IMS)
  29. 29. Why strategic planning is important 2009 global generic products generated $83bn (€59.8bn) in audited sales (IMS) In the $59bn global generics market in developed countries, Japan only accounts for 6%, while the US holds 42%, and five major European national markets account for 23%. BCC estimates the global market to reach $129.3bn by 2014, representing a 9% annual growth rate.
  30. 30. Why strategic planning is important 2009 global generic products generated $83bn (€59.8bn) in audited sales, according to IMS. In the $59bn global generics market in developed countries, Japan only accounts for 6%, while the US holds 42%, and five major European national markets account for 23%. BCC estimates the global market to reach $129.3bn by 2014, representing a 9% annual growth rate. 29% $37.5bn Undeveloped markets
  31. 31. Why strategic planning is important Government debt as % of GDP (2009)
  32. 32. Why strategic planning is important
  33. 33. Why strategic planning is important
  34. 34. Why strategic planning is important IMS estimates that sales from the top 10 US generic players grew at an average of 13.2% in 2009 The big are getting bigger!
  35. 35. Why strategic planning is important The big can get bigger still!
  36. 36. Why strategic planning is important The big can get bigger still! &quot;Only those who are agile and strong will survive in this business,&quot; said Teva president and CEO Shlomo Yanai during the company's investor meeting last month in Jerusalem. &quot;About 15% of our business will come from acquisitions . We are taking the necessary steps and building our infrastructure by getting assets and know-how either internally, through acquisition or partnerships.&quot; Teva estimates its 2009 global sales at $13.9bn, of which 70% are from generic products. Yanai is targeting $31bn in sales by 2015 , of which 70% will still come from generics.
  37. 37. Why strategic planning is important The big can get bigger still! Teva estimates its 2009 global sales at $13.9bn, of which 70% are from generic products. Yanai is targeting $31bn in sales by 2015, of which 70% will still come from generics. &quot;Only those who are agile and strong will survive in this business,&quot;
  38. 38. Why strategic planning is important Biosimilars/follow on biologics Approximately one-third of all newly approved drugs will be biologics. (2010)  Double-digit growth of 20 percent, they generated $95 billion of sales amounting to approximately 15 percent of global pharma revenues. Today, total sales of off-patent biologics amount to approximately $20 billion The average costs of biologic drug treatment is about $72,000/year (compared to about $1,000 for conventional &quot;small molecule&quot; pharmaceuticals)
  39. 39. Why strategic planning is important
  40. 40. Why strategic planning is important Biosimilars/follow on biologics
  41. 41. Why strategic planning is important The patent cliff: 2010-15 Of total pharmaceutical sales in 2008 of $643.6bn, a staggering 30% were derived from patented products which are “at risk” from generic competition within five years, almost double the percentage at risk in 2000 of 17%. Whilst the industry has already started its slide, the patent cliff becomes seriously precipitous in 2010 when 9%, or $57.5bn , of total market sales are expected to lose patent protection within the space of 12 months
  42. 42. Why strategic planning is important The patent cliff: 2010-15 The world's top drugmakers face the loss of $140 billion in annual sales by 2016 (of $700bn 2008)
  43. 43. Why strategic planning is important The patent cliff: 2010-15 Inhalation market Approximately 50% of the current $32 billion global market segment for asthma and COPD medicines is expected to lose patent protection by the end of 2016 , according to industry analysts IMS Health. The asthma and COPD market segment is projected to grow significantly faster than the pharmaceutical market, driven by factors including a significant level of under-diagnosis, and Novartis/Sandoz will hope this acquisition will gain them a large market share in the future. Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company, gaining exclusive rights to a portfolio of generic drug candidates and related technologies targeting medicines in the inhalable respiratory drug market. Holzkirchen, Germany, April 19, 2010
  44. 44. Why strategic planning is important The patent cliff: 2010-15 &quot;There is still room to grow in generics,&quot; says Yanai (TEVA). &quot; Almost $150bn of branded drugs are going to be off patent in the next five years . This does not include the expiration of biologics , which is an additional $50bn potential.”
  45. 45. Overview of typical generic portfolio’s <ul><li>The patent cliff: 2010-15 </li></ul><ul><li>Whats the big pharma plan? </li></ul><ul><li>More investment in R&D? </li></ul><ul><li>Clever anti-generic tactics? </li></ul><ul><li>Switch out before expiry strategies? </li></ul><ul><li>Increase legal spend on ever-greening patents? </li></ul><ul><li>Big budget advertising in BRIC markets? </li></ul>
  46. 46. The patent cliff: 2010-15. Whats the big pharma plan? Astra Zeneca announced today that it has agreed to market 18 of Torrent Pharmaceuticals Ltd.’s branded generic drugs in 9 emerging markets , marking the U.K. drugmaker’s first generic-drug partnership. Unlike some its competitors, Astra Zeneca is very vulnerable to generic competition as many of its best selling products such as Nexium for ulcers, the antipsychotic Seroquel and Crestor for cholesterol. are near patent expiry. Industry analysts expect the company to lose as much as 25% of its sales revenue to generic encroachment by 2014. Why strategic planning is important
  47. 47. The patent cliff: 2010-15. Whats the big pharma plan? Sanofi-Aventis bought Zentiva NV of the Czech Republic, Helvepharm AG of Switzerland, Medley SA of Brazil and Laboratorios Kendrick SA of Mexico to bolster its branded generics portfolio. Why strategic planning is important
  48. 48. The patent cliff: 2010-15. Whats the big pharma plan? “ Generics are an important part of the health care system. ????? believes that when there is a direct generic equivalent to the prescribed brand name drug, it should be used provided the doctor agrees it is best for the patient.” Why strategic planning is important
  49. 49. The patent cliff: 2010-15. Whats the big pharma plan? “ Generics are an important part of the health care system. Pfizer believes that when there is a direct generic equivalent to the prescribed brand name drug, it should be used provided the doctor agrees it is best for the patient.” http://www.pfizer.com/about/public_policy/generics.jsp Why strategic planning is important
  50. 50. The patent cliff: 2010-15. Whats the big pharma plan? NEW YORK, March 18 (Reuters) - Pfizer Inc ( PFE.N ) may still be eager to buy generic drugmakers, after being outbid for Germany's Ratiopharm in an effort to shore up revenue as it braces for evaporating sales of its blockbuster Lipitor cholesterol treatment. Pfizer’s expanded agreements with Aurobindo Pharma Ltd. will grow its generic product portfolio within emerging markets to reflect the diverse and often unique market dynamics and commercial interests of more than 70 countries. Pfizer entered into agreements with Claris Lifesciences Ltd. (“Claris”) to commercialize sterile injectable medicines after the products are no longer patent protected , and have lost market exclusivity in North America, Europe, Australia and New Zealand. The Claris agreements advance Pfizer’s Established Products strategy, which focuses on the commercialization of products where market exclusivity has been lost. Pfizer’s global annual sales of established products are approximately $10 billion. Why strategic planning is important
  51. 51. The patent cliff: 2010-15. Whats the big pharma plan? Pfizer’s global annual sales of established products are approximately $10 billion (?!) Why strategic planning is important
  52. 52. The patent cliff: 2010-15. Whats the big pharma plan? Last year, GlaxoSmithKline entered into joint ventures with the generic manufacturers Dr. Reddy’s Laboratories (India) and Aspen Pharmacare Ltd (South Africa). Also, the company paid $246.5 million for Bristol-Myers Squibb’s Pakistan and Egypt drug units and acquired UCB’s drug portfolio in Africa, the Middle East, Asia Pacific and Latin America for $702 million; clearing signaling its intention to more aggressively pursue emerging global markets . Why strategic planning is important
  53. 53. Why strategic planning is important <ul><li>SUMMARY : What is the future going to look like?! </li></ul><ul><li>5 year high growth window </li></ul><ul><li>Major player strength & depth </li></ul><ul><li>Biologics </li></ul><ul><li>Big pharma entering generics </li></ul>
  54. 54. Introduction to sourcing from 3rd parties <ul><li>Creating the portfolio – why look outside </li></ul><ul><li>Manufacturing constraints </li></ul><ul><li>Development capability </li></ul><ul><li>Time to revenue </li></ul><ul><li>Financial status </li></ul><ul><li>Product mix </li></ul><ul><li>Country/region specific products </li></ul><ul><li>Tactical & strategic relationships </li></ul><ul><li>Strong and agile Teva in-licenses 30% of products! </li></ul>
  55. 55. Introduction to sourcing from 3rd parties <ul><li>Creating the portfolio – where to look </li></ul><ul><li>Emerging markets </li></ul><ul><ul><li>EU ascension states </li></ul></ul><ul><ul><li>High Tech Far East (Korea, Taiwan) </li></ul></ul><ul><ul><li>Well developed Latin America </li></ul></ul><ul><li>Online </li></ul><ul><ul><li>New databases </li></ul></ul><ul><ul><li>Forums and discussion groups </li></ul></ul><ul><ul><li>Virtual partnering events </li></ul></ul>
  56. 56. Introduction to sourcing from 3rd parties <ul><li>Creating the portfolio – considerations </li></ul><ul><li>Partner Selection </li></ul><ul><ul><li>Commercial relationship model </li></ul></ul><ul><ul><li>Quality and consistency of supply </li></ul></ul><ul><ul><li>Long term cost position </li></ul></ul><ul><ul><li>Partner’s ambitions </li></ul></ul><ul><li>Beware… </li></ul><ul><ul><li>Regulatory expertise </li></ul></ul><ul><ul><li>Number of dossiers/licenses sold </li></ul></ul><ul><ul><li>IP ownership and supply chain flexibility </li></ul></ul>
  57. 57. Summary <ul><li>What type of portfolio do you want? - Selecting generic products isn’t easy </li></ul><ul><li>- Why strategic planning is important for generic companies </li></ul><ul><li>The other option; in-license & partner </li></ul><ul><li>That is why strategy and planning for generic portfolio’s is required! </li></ul>

×